Zobrazeno 1 - 10
of 785
pro vyhledávání: '"Minoru FUKUDA"'
Autor:
Hiromi Tomono, Hirokazu Taniguchi, Minoru Fukuda, Takaya Ikeda, Seiji Nagashima, Kazumasa Akagi, Sawana Ono, Yasuhiro Umeyama, Midori Shimada, Hiroshi Gyotoku, Shinnosuke Takemoto, Yasushi Hisamatsu, Ryotaro Morinaga, Ryuta Tagawa, Ryosuke Ogata, Yosuke Dotsu, Hiroaki Senju, Hiroshi Soda, Katsumi Nakatomi, Fumiko Hayashi, Nanae Sugasaki, Akitoshi Kinoshita, Hiroshi Mukae
Publikováno v:
Thoracic Cancer, Vol 14, Iss 28, Pp 2890-2894 (2023)
Abstract Introduction Combined treatment using anti‐programmed death‐ligand 1 antibody (anti‐PD‐L1) and platinum‐etoposide is the current standard first‐line treatment for patients with extensive‐stage (ES) small cell lung cancer (SCLC)
Externí odkaz:
https://doaj.org/article/58002b57502d40c3b42c6726aa5a9340
Autor:
Kanako Sakaeda, Koji Kurose, Yuki Matsumura, Satoshi Muto, Minoru Fukuda, Nanae Sugasaki, Masaaki Fukuda, Shinnosuke Takemoto, Hirokazu Taniguchi, Takeshi Masuda, Katsuhiko Shimizu, Yuki Kataoka, Yasuhiro Irino, Yumiko Sakai, Yusuke Atarashi, Masatoshi Yanagida, Noboru Hattori, Hiroshi Mukae, Masao Nakata, Eiichiro Kanda, Toru Oga, Hiroyuki Suzuki, Mikio Oka
Publikováno v:
Cancer Treatment and Research Communications, Vol 40, Iss , Pp 100830- (2024)
Background: NY-ESO-1 and XAGE1 cancer/testis antigens elicit humoral and cellular immune responses in NSCLC patients. We aimed to predict clinical benefit with ICI monotherapy, using an automated immunoassay of NY-ESO-1/XAGE1 antibodies (Abs). Method
Externí odkaz:
https://doaj.org/article/fa49acdde51b426e87156baacb0661b1
Autor:
Kazushige Wakuda, MD, Hiroyuki Yamaguchi, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Minoru Fukuda, MD, PhD, Kentaro Ito, MD, Yuko Tsuchiya-Kawano, MD, PhD, Kentaro Tanaka, MD, PhD, Taishi Harada, MD, PhD, Yuki Nakatani, MD, Satoru Miura, MD, Toshihide Yokoyama, MD, Tomomi Nakamura, MD, Miiru Izumi, MD, PhD, Atsushi Nakamura, MD, PhD, Satoshi Ikeda, MD, PhD, Koichi Takayama, MD, PhD, Kenichi Yoshimura, PhD, Kazuhiko Nakagawa, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Kenji Sugio, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100587- (2023)
Introduction: Osimertinib may be effective in treating central nervous system (CNS) metastasis, but its efficacy in treating radiation therapy (RT)-naive metastasis is unclear. The OCEAN study assessed the efficacy of osimertinib against RT-naive CNS
Externí odkaz:
https://doaj.org/article/2430d3ab5e8943f5b2079f35a13f2fad
Autor:
Minoru Fukuda, Masafumi Yamaguchi, Takuya Yamazaki, Soichiro Funaki, Hiroshi Mukae, Junya Fukuoka, Kazuki Nabeshima, Hisashi Tateyama, Kazuto Ashizawa, Noriyuki Tomiyama, Masaki Hara, Takashi Seto, Meinoshin Okumura, Kenji Sugio
Publikováno v:
Thoracic Cancer, Vol 13, Iss 17, Pp 2499-2506 (2022)
Abstract Background Combination chemotherapy is used to treat advanced thymic carcinoma; however, the effects are insufficient. Methods Previously untreated patients with unresectable locally advanced thymic carcinoma received two cycles of 80 mg/m2/
Externí odkaz:
https://doaj.org/article/d52d8cef8a754bf9bf9f39046dc2b873
Autor:
Kazumasa Akagi, Hirokazu Taniguchi, Minoru Fukuda, Takuya Yamazaki, Sawana Ono, Hiromi Tomono, Takayuki Suyama, Midori Shimada, Hiroshi Gyotoku, Shinnosuke Takemoto, Hiroyuki Yamaguchi, Yosuke Dotsu, Hiroaki Senju, Hiroshi Soda, Takashi Mizowaki, Yoshio Monzen, Takaya Ikeda, Seiji Nagashima, Yutaro Tasaki, Daisuke Nakamura, Kazutoshi Komiya, Katsumi Nakatomi, Eisuke Sasaki, Koichi Hirakawa, Hiroshi Mukae
Publikováno v:
Thoracic Cancer, Vol 13, Iss 16, Pp 2404-2409 (2022)
Abstract Background Etoposide plus cisplatin (EP) combined with concurrent accelerated hyperfractionated thoracic radiotherapy (AHTRT) is the standard treatment strategy for unresectable limited‐disease (LD) small cell lung cancer (SCLC), which has
Externí odkaz:
https://doaj.org/article/e98bad858982435187389e1927d39f13
Autor:
Shinnosuke Takemoto, Kazumasa Akagi, Sawana Ono, Hiromi Tomono, Noritaka Honda, Takayuki Suyama, Yasuhiro Umeyama, Yosuke Dotsu, Hirokazu Taniguchi, Daiki Ogawara, Hiroaki Senju, Hiroshi Gyotoku, Nanae Sugasaki, Hiroyuki Yamaguchi, Katsumi Nakatomi, Minoru Fukuda, Hiroshi Mukae
Publikováno v:
Thoracic Cancer, Vol 12, Iss 17, Pp 2300-2306 (2021)
Abstract Background S‐1 and pemetrexed (PEM) are key treatments for non‐small cell lung cancer (NSCLC). However, the mechanism of anticancer activity of S‐1 and PEM is similar. Cross‐resistance between S‐1 and PEM is of concern. This explor
Externí odkaz:
https://doaj.org/article/602db2692a2a4097822cef7b5d6f304e
Autor:
Naoko Sueoka‐Aragane, Chiho Nakashima, Hironori Yoshida, Naohisa Matsumoto, Kentaro Iwanaga, Noriyuki Ebi, Akihiro Nishiyama, Kazuhiro Yatera, Shoichi Kuyama, Minoru Fukuda, Sunao Ushijima, Hitomi Umeguchi, Daijiro Harada, Kosuke Kashiwabara, Takayuki Suetsugu, Nobukazu Fujimoto, Fumihiro Tanaka, Hidetaka Uramoto, Chiharu Yoshii, Katsumi Nakatomi, Genju Koh, Nobuhiko Seki, Keisuke Aoe, Kaname Nosaki, Koji Inoue, Ayako Takamori, Atsushi Kawaguchi
Publikováno v:
Cancer Medicine, Vol 10, Iss 12, Pp 3873-3885 (2021)
Abstract Background EGFR mutations are good predictive markers of efficacy of EGFR tyrosine kinase inhibitors (EGFR‐TKI), but whether comprehensive genomic analysis beyond EGFR itself with circulating tumor DNA (ctDNA) adds further predictive or pr
Externí odkaz:
https://doaj.org/article/9fdb0934bf3d40bbb7a19d2b98a77955
Autor:
Hirokazu Taniguchi, Shinnosuke Takemoto, Mutsumi Ozasa, Noritaka Honda, Takayuki Suyama, Yasuhiro Umeyama, Yosuke Dotsu, Takumi Nakao, Kojima Tomohito, Hiroshi Gyotoku, Hiroyuki Yamaguchi, Taiga Miyazaki, Noriho Sakamoto, Yasushi Obase, Minoru Fukuda, Junya Fukuoka, Hiroshi Mukae
Publikováno v:
Thoracic Cancer, Vol 12, Iss 7, Pp 1126-1130 (2021)
Abstract Pulmonary sarcomatoid carcinoma (SC) is an aggressive subtype of lung cancer that exhibits resistance to cytotoxic chemotherapy. Although programmed cell death 1 (PD‐1) inhibitors have been reported to show antitumor effects in patients wi
Externí odkaz:
https://doaj.org/article/6e73f2b7182941efb6805ba97152256a
Autor:
Takaya Ikeda, Shinnosuke Takemoto, Hiroaki Senju, Hiroshi Gyotoku, Hirokazu Taniguchi, Midori Shimada, Yosuke Dotsu, Yasuhiro Umeyama, Hiromi Tomono, Takeshi Kitazaki, Masaaki Fukuda, Hiroshi Soda, Hiroyuki Yamaguchi, Minoru Fukuda, Hiroshi Mukae
Publikováno v:
Thoracic Cancer, Vol 11, Iss 7, Pp 1972-1978 (2020)
Background The aim of this study was to assess the efficacy and safety of amrubicin for previously treated malignant pleural mesothelioma. Methods The eligibility criteria were: previously treated unresectable malignant pleural mesothelioma; performa
Externí odkaz:
https://doaj.org/article/b8beb7e2f14e48d293606d434ed3eea7
Autor:
Kazushige Wakuda, Hiroyuki Yamaguchi, Hirotsugu Kenmotsu, Minoru Fukuda, Masafumi Takeshita, Takayuki Suetsugu, Keisuke Kirita, Noriyuki Ebi, Osamu Hataji, Satoru Miura, Kenji Chibana, Isamu Okamoto, Kenichi Yoshimura, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Kenji Sugio
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-6 (2020)
Abstract Background Patients with activating epidermal growth factor receptor (EGFR) mutations are highly responsive to EGFR-tyrosine kinase inhibitors (TKIs). However, it has been reported that approximately 15–30% of patients treated with EGFR-TK
Externí odkaz:
https://doaj.org/article/c4884704459847fb8984edec803f99a8